BioStem Evaluates $10 Million to $12 Million in Annual Cash Cost Cuts

Your call?🐂 Bullish🐻 Bearish

Management expects operating expenses to decline and adjusted EBITDA losses to narrow in 2027. The planned manufacturing shift remains subject to validation and regulatory requirements.